Dutch Bio Science Week 2025 has brought an extraordinary buzz to Leiden, transforming the city and the Bio Science Park into a hub of discovery, connection, and inspiration. Over the past days, professionals, researchers, students, and curious visitors have come…
The Court of Audit visited LBSP to explore how science and entrepreneurship create public value, with stops at TNO, Peregrion, NTrans, and VarmX sparking discussion on biotech innovation.
Leiden University is studying emotions at Lowlands Festival through two projects: a haunted house that measures how people cope with fear, and a silent performance exploring nonverbal communication.
LUMC and Stichting DON have launched Cure One, a new research center focused on accelerating curative therapies for type 1 diabetes through stem cell technology and immune-based treatments.
Thank you to everyone who joined us last Thursday at Grand Café de Stal. The room was full of energy, curiosity, and conversation as we explored the next wave of biotech innovation together. A special thanks to our speakers: 🟠…
Four Leiden University researchers have each received €2.5 million ERC Advanced Grants to pursue innovative projects in social inequality, medical placebo effects, type 1 diabetes treatment, and community-based climate adaptation, aiming to make significant scientific and societal contributions.
At BIO International Convention in Boston, biotech ambition turns into partnership and progress. This year, Leiden Bio Science Park joined the Dutch delegation at the Netherlands Pavilion, right alongside innovators, investors, and policymakers all working to shape the future of…
Professor Bart Roep of LUMC has received a €2.5 million ERC Advanced Grant to develop a potential cure for type 1 diabetes by creating immune-resistant insulin-producing cells. His research focuses on reducing beta cell stress and using targeted drug delivery…
We recently hosted Tjerk Opmeer from the Ministry of Economic Affairs at Leiden Bio Science Park to share insights into building a shared investment agenda for Dutch biotech. Joined by leaders from universities, industry, and government, Esther Peters from Leiden…
A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify…
The first Works Council Community meeting at Leiden Bio Science Park tackled workplace conduct and culture through honest, practical dialogue. With HR and legal experts in the room, the session marked the start of a collaborative effort to foster safer,…
EMA visited Leiden Bio Science Park to explore how regulatory tools can better support early-stage innovation. The visit connected EMA representatives with local leaders across academia, investment, and biotech development for a forward-looking exchange on speeding therapies to patients.